Spark Acquires Irish Ophthalmology Partner
This article was originally published in Scrip
Executive Summary
Philadelphia-based Spark Therapeutics has acquired private, Irish gene therapy company, Genable Technologies, for $6m in cash and 265,000 shares of Spark common stock.